Advertisement
Screener

ARDELYX, INC. (ARDX) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

ARDELYX, INC. Research and Development Expense

ARDELYX, INC. (ARDX) reported Research and Development Expense of $26.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06

  • ARDELYX, INC. research and development expense for the quarter ending 2026-06-30 was $26.10M, a 66.62% increase year-over-year.
  • ARDELYX, INC. research and development expense for the quarter ending 2026-03-31 was $20.19M, a 35.15% increase year-over-year.
  • ARDELYX, INC. research and development expense for the quarter ending 2025-12-31 was $22.86M, a 67.25% increase year-over-year.
  • ARDELYX, INC. research and development expense for the quarter ending 2025-09-30 was $18.07M, a 18.01% increase year-over-year.
  • ARDELYX, INC. research and development expense for fiscal 2025 was $71.53M, a 36.72% increase from fiscal 2024.
  • ARDELYX, INC. research and development expense for fiscal 2024 was $52.32M, a 47.22% increase from fiscal 2023.
  • ARDELYX, INC. research and development expense for fiscal 2023 was $35.54M, a 0.95% increase from fiscal 2022.
  • ARDELYX, INC. research and development expense for fiscal 2022 was $35.20M, a 61.38% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$26.10M
10-Q · filed 2026-08-06
$46.29M
10-Q · filed 2026-08-06
$69.15M
derived: sum of 3 quarters · filed 2026-08-06
$87.21M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$20.19M
10-Q · filed 2026-04-30
$43.04M
derived: sum of 2 quarters · filed 2026-04-30
$61.11M
derived: sum of 3 quarters · filed 2026-04-30
$76.78M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$22.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$40.92M
derived: sum of 2 quarters · filed 2026-02-19
$56.59M
derived: sum of 3 quarters · filed 2026-08-06
$71.53M
10-K · filed 2026-02-19
2025-09-30$18.07M
10-Q · filed 2025-10-30
$33.73M
derived: sum of 2 quarters · filed 2026-08-06
$48.67M
10-Q · filed 2025-10-30
$62.34M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$15.67M
10-Q · filed 2026-08-06
$30.60M
10-Q · filed 2026-08-06
$44.27M
derived: sum of 3 quarters · filed 2026-08-06
$59.58M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$14.94M
10-Q · filed 2026-04-30
$28.60M
derived: sum of 2 quarters · filed 2026-04-30
$43.91M
derived: sum of 3 quarters · filed 2026-04-30
$56.68M
derived: sum of 4 quarters · filed 2026-04-30
2024-12-31$13.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$28.98M
derived: sum of 2 quarters · filed 2026-02-19
$41.74M
derived: sum of 3 quarters · filed 2026-02-19
$52.32M
10-K · filed 2026-02-19
2024-09-30$15.31M
10-Q · filed 2025-10-30
$28.07M
derived: sum of 2 quarters · filed 2025-10-30
$38.65M
10-Q · filed 2025-10-30
$48.17M
derived: sum of 4 quarters · filed 2026-02-19
2024-06-30$12.76M
10-Q · filed 2025-08-04
$23.34M
10-Q · filed 2025-08-04
$32.87M
derived: sum of 3 quarters · filed 2026-02-19
$41.50M
derived: sum of 4 quarters · filed 2026-02-19
2024-03-31$10.58M
10-Q · filed 2025-05-01
$20.10M
derived: sum of 2 quarters · filed 2026-02-19
$28.74M
derived: sum of 3 quarters · filed 2026-02-19
$37.02M
derived: sum of 4 quarters · filed 2026-02-19
2023-12-31$9.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$18.16M
derived: sum of 2 quarters · filed 2026-02-19
$26.44M
derived: sum of 3 quarters · filed 2026-02-19
$35.54M
10-K · filed 2026-02-19
2023-09-30$8.64M
10-Q · filed 2024-10-31
$16.92M
derived: sum of 2 quarters · filed 2024-10-31
$26.01M
10-Q · filed 2024-10-31
$35.15M
derived: sum of 4 quarters · filed 2025-02-20
2023-06-30$8.28M
10-Q · filed 2024-08-01
$17.38M
10-Q · filed 2024-08-01
$26.52M
derived: sum of 3 quarters · filed 2025-02-20
$33.98M
derived: sum of 4 quarters · filed 2025-02-20
2023-03-31$9.09M
10-Q · filed 2024-05-02
$18.23M
derived: sum of 2 quarters · filed 2025-02-20
$25.70M
derived: sum of 3 quarters · filed 2025-02-20
$35.44M
derived: sum of 4 quarters · filed 2025-02-20
2022-12-31$9.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20
$16.61M
derived: sum of 2 quarters · filed 2025-02-20
$26.35M
derived: sum of 3 quarters · filed 2025-02-20
$35.20M
10-K · filed 2025-02-20
2022-09-30$7.47M
10-Q · filed 2023-10-31
$17.21M
derived: sum of 2 quarters · filed 2023-10-31
$26.06M
10-Q · filed 2023-10-31
$47.03M
derived: sum of 4 quarters · filed 2024-02-22
2022-06-30$9.74M
10-Q · filed 2023-08-02
$18.59M
10-Q · filed 2023-08-02
$39.56M
derived: sum of 3 quarters · filed 2024-02-22
$63.26M
derived: sum of 4 quarters · filed 2024-02-22
2022-03-31$8.85M
10-Q · filed 2023-05-03
$29.82M
derived: sum of 2 quarters · filed 2024-02-22
$53.51M
derived: sum of 3 quarters · filed 2024-02-22
$79.53M
derived: sum of 4 quarters · filed 2024-02-22
2021-12-31$20.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22
$44.66M
derived: sum of 2 quarters · filed 2024-02-22
$70.68M
derived: sum of 3 quarters · filed 2024-02-22
$91.14M
10-K · filed 2024-02-22
2021-09-30$23.70M
10-Q · filed 2022-11-03
$49.72M
derived: sum of 2 quarters · filed 2022-11-03
$70.17M
10-Q · filed 2022-11-03
$88.28M
derived: sum of 4 quarters · filed 2023-03-02
2021-06-30$26.02M
10-Q · filed 2022-08-04
$46.48M
10-Q · filed 2022-08-04
$64.58M
derived: sum of 3 quarters · filed 2023-03-02
$76.82M
derived: sum of 4 quarters · filed 2023-03-02
2021-03-31$20.46M
10-Q · filed 2022-05-05
$38.56M
derived: sum of 2 quarters · filed 2023-03-02
$50.80M
derived: sum of 3 quarters · filed 2023-03-02
$69.67M
derived: sum of 4 quarters · filed 2023-03-02
2020-12-31$18.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
$30.34M
derived: sum of 2 quarters · filed 2023-03-02
$49.21M
derived: sum of 3 quarters · filed 2023-03-02
$65.05M
10-K · filed 2023-03-02
2020-09-30$12.24M
10-Q · filed 2021-11-12
$31.10M
derived: sum of 2 quarters · filed 2021-11-12
$46.95M
10-Q · filed 2021-11-12
$61.19M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$18.86M
10-Q · filed 2021-08-13
$34.71M
10-Q · filed 2021-08-13
$48.95M
derived: sum of 3 quarters · filed 2022-02-28
$66.53M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$15.84M
10-Q · filed 2021-05-06
$30.09M
derived: sum of 2 quarters · filed 2022-02-28
$47.66M
derived: sum of 3 quarters · filed 2022-02-28
$67.14M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$14.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$31.82M
derived: sum of 2 quarters · filed 2022-02-28
$51.30M
derived: sum of 3 quarters · filed 2022-02-28
$71.68M
10-K · filed 2022-02-28
2019-09-30$17.58M
10-Q · filed 2020-11-05
$37.05M
derived: sum of 2 quarters · filed 2020-11-05
$57.44M
10-Q · filed 2020-11-05
$79.47M
derived: sum of 4 quarters · filed 2021-03-08
2019-06-30$19.48M
10-Q · filed 2020-08-06
$39.86M
10-Q · filed 2020-08-06
$61.89M
derived: sum of 3 quarters · filed 2021-03-08
$79.83M
derived: sum of 4 quarters · filed 2021-03-08
2019-03-31$20.38M
10-Q · filed 2020-05-07
$42.42M
derived: sum of 2 quarters · filed 2021-03-08
$60.36M
derived: sum of 3 quarters · filed 2021-03-08
$76.40M
derived: sum of 4 quarters · filed 2021-03-08
2018-12-31$22.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08
$39.98M
derived: sum of 2 quarters · filed 2021-03-08
$56.02M
derived: sum of 3 quarters · filed 2021-03-08
$69.37M
10-K · filed 2021-03-08
2018-09-30$17.94M
10-Q · filed 2019-11-06
$33.99M
derived: sum of 2 quarters · filed 2019-11-06
$47.34M
10-Q · filed 2019-11-06
$64.50M
derived: sum of 4 quarters · filed 2020-03-06
2018-06-30$16.05M
10-Q · filed 2019-08-09
$29.40M
10-Q · filed 2019-08-09
$46.55M
derived: sum of 3 quarters · filed 2020-03-06
$61.92M
derived: sum of 4 quarters · filed 2020-03-06
2018-03-31$13.35M
10-Q · filed 2019-05-07
$30.51M
derived: sum of 2 quarters · filed 2020-03-06
$45.87M
derived: sum of 3 quarters · filed 2020-03-06
$66.45M
derived: sum of 4 quarters · filed 2020-03-06
2017-12-31$17.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06
$32.52M
derived: sum of 2 quarters · filed 2020-03-06
$53.10M
derived: sum of 3 quarters · filed 2020-03-06
$75.48M
10-K · filed 2020-03-06
2017-09-30$15.37M
10-Q · filed 2018-11-07
$35.94M
derived: sum of 2 quarters · filed 2018-11-07
$58.33M
10-Q · filed 2018-11-07
$84.53M
derived: sum of 4 quarters · filed 2019-03-06
2017-06-30$20.57M
10-Q · filed 2018-08-07
$42.96M
10-Q · filed 2018-08-07
$69.17M
derived: sum of 3 quarters · filed 2019-03-06
$94.03M
derived: sum of 4 quarters · filed 2019-03-06
2017-03-31$22.39M
10-Q · filed 2018-05-08
$48.60M
derived: sum of 2 quarters · filed 2019-03-06
$73.46M
derived: sum of 3 quarters · filed 2019-03-06
$97.30M
derived: sum of 4 quarters · filed 2019-03-06
2016-12-31$26.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06
$51.07M
derived: sum of 2 quarters · filed 2019-03-06
$74.91M
derived: sum of 3 quarters · filed 2019-03-06
$94.16M
10-K · filed 2019-03-06
2016-09-30$24.86M
10-Q · filed 2017-11-07
$48.70M
derived: sum of 2 quarters · filed 2017-11-07
$67.95M
10-Q · filed 2017-11-07
$80.73M
derived: sum of 4 quarters · filed 2018-03-14
2016-06-30$23.84M
10-Q · filed 2017-08-09
$43.09M
10-Q · filed 2017-08-09
$55.87M
derived: sum of 3 quarters · filed 2018-03-14
$70.58M
derived: sum of 4 quarters · filed 2018-03-14
2016-03-31$19.25M
10-Q · filed 2017-05-05
$32.03M
derived: sum of 2 quarters · filed 2018-03-14
$46.74M
derived: sum of 3 quarters · filed 2018-03-14
$52.94M
derived: sum of 4 quarters · filed 2018-03-14
2015-12-31$12.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14
$27.49M
derived: sum of 2 quarters · filed 2018-03-14
$33.69M
derived: sum of 3 quarters · filed 2018-03-14
$39.88M
10-K · filed 2018-03-14
2015-09-30$14.71M
10-Q · filed 2016-11-07
$20.90M
derived: sum of 2 quarters · filed 2016-11-07
$27.10M
10-Q · filed 2016-11-07
$34.49M
derived: sum of 4 quarters · filed 2017-02-17
2015-06-30$6.20M
10-Q · filed 2016-08-08
$12.40M
10-Q · filed 2016-08-08
$19.78M
derived: sum of 3 quarters · filed 2017-02-17
$25.48M
derived: sum of 4 quarters · filed 2017-02-17
2015-03-31$6.20M
10-Q · filed 2016-05-09
$13.58M
derived: sum of 2 quarters · filed 2017-02-17
$19.28M
derived: sum of 3 quarters · filed 2017-02-17
$24.46M
derived: sum of 4 quarters · filed 2017-02-17
2014-12-31$7.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17
$13.08M
derived: sum of 2 quarters · filed 2017-02-17
$18.26M
derived: sum of 3 quarters · filed 2017-02-17
$25.90M
10-K · filed 2017-02-17
2014-09-30$5.69M
10-Q · filed 2015-11-12
$10.88M
derived: sum of 2 quarters · filed 2015-11-12
$18.51M
10-Q · filed 2015-11-12
$26.85M
derived: sum of 4 quarters · filed 2016-03-04
2014-06-30$5.18M
10-Q · filed 2015-08-12
$12.82M
10-Q · filed 2015-08-12
$21.16M
derived: sum of 3 quarters · filed 2016-03-04
$27.74M
derived: sum of 4 quarters · filed 2016-03-04
2014-03-31$7.64M
10-Q · filed 2015-05-12
$15.97M
derived: sum of 2 quarters · filed 2016-03-04
$22.56M
derived: sum of 3 quarters · filed 2016-03-04
$29.79M
derived: sum of 4 quarters · filed 2016-03-04
2013-12-31$8.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04
$14.92M
derived: sum of 2 quarters · filed 2016-03-04
$22.15M
derived: sum of 3 quarters · filed 2016-03-04
$28.09M
10-K · filed 2016-03-04
2013-09-30$6.58M
10-Q · filed 2014-11-07
$13.82M
derived: sum of 2 quarters · filed 2014-11-07
$19.76M
10-Q · filed 2014-11-07
2013-06-30$7.23M
10-Q · filed 2014-08-08
$13.17M
10-Q · filed 2014-08-08
2012-12-31$10.18M
10-K · filed 2015-03-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Cryoport, Inc. (CYRX)United States$0.881B-21.29
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
Apnimed, Inc. (APMD)United States$0.899B
GERON CORP (GERN)United States$0.803B-12.14